Dilution of share value from the exercise of stock acquisition rights
First written in FY2020. 16 of 19 entries say "Materialised", first in FY2021-Q2. Latest entry: FY2027-H1.
VisasQ moved to the "Worse" side of this theme in 2020, the same year as the typical company in this theme.
The whole theme swung hardest in 2017: 37 of 68 companies on the "Worse" side.
69 other companies' latest entry also says "Materialised".
- FY2027-H1MaterialisedAnnual report
「1 March 2026 〜 31 August 2026 (Note) 5 Common shares 8,750 Common shares 9,284,922 Class A shares 75,000 Class B shares 13,609 189 486,108 － 367,076 (Note) 5. These resulted from the exercise of stock acquisition rights.」
During the current interim consolidated accounting period, 8,750 common shares were issued through the exercise of stock acquisition rights, and share issuances that could lead to dilution have continued. - FY2026WorsenedAnnual report
「As of the end of the current consolidated fiscal year, potential shares, including class shares and stock acquisition rights issued for the acquisition of Coleman Research Group, Inc. and stock acquisition rights issued to the Company's officers and employees, totaled 3,380,349, equivalent to approximately 36% of the 9,353,317 issued shares, including class shares and treasury shares.」
Potential shares totaled 3,380,349, equivalent to approximately 36% of the total number of issued shares, up from approximately 35% in the previous fiscal year, indicating a higher potential dilution ratio. - 2026-05-08MaterialisedGeneral Meetings of Shareholders
「Common shares 9,247,500 shares 17,000 shares － shares 9,264,500 shares」
The company stated that the increase of 17,000 common shares during the fiscal year resulted from the exercise of stock acquisition rights and the issuance of shares under the PSU. It also stated that the number of common shares underlying stock acquisition rights at fiscal year-end was 580,250. - FY2026-H1MaterialisedAnnual report
「1 March 2025–31 August 2025 (Note 2) Common shares 8,000 (Note 2) Resulting from the exercise of stock acquisition rights.」
During the current interim consolidated accounting period, 8,000 common shares were issued through the exercise of stock acquisition rights, confirming the continued issuance of shares capable of causing dilution. - FY2025MaterialisedAnnual report
「As of the end of the current consolidated fiscal year, potential shares, including class shares and stock acquisition rights issued for the acquisition of Coleman Research Group, Inc. and stock acquisition rights issued to the Company's officers and employees, totaled 3,311,494, equivalent to approximately 35% of the 9,336,317 issued shares, including class shares and treasury shares.」
The Company continues to quantitatively disclose the potential for dilution, with potential shares of 3,311,494 equivalent to approximately 35% of the total number of issued shares. In addition, 31,400 common shares were issued through the exercise of stock acquisition rights during the period. - FY2025-H1MaterialisedAnnual report
「1 March 2024–31 August 2024 (Notes 2 and 3) Common shares 24,450 …… (Note 2) Resulting from the exercise of stock acquisition rights. 3. Between 1 September 2024 and 30 September 2024, the exercise of stock acquisition rights increased the total number of issued shares by 5,500 and capital stock by ¥1.084 million.」
During the current interim consolidated accounting period, 24,450 common shares were issued through the exercise of stock acquisition rights, and a further 5,500 shares were issued in September 2024. - FY2025-Q1MaterialisedAnnual report
「The stock acquisition rights issued under the Companies Act during the current first quarter accounting period are as follows. Class, description and number of shares underlying the stock acquisition rights (shares) * Common shares 92,000」
The fifteenth series of stock acquisition rights was issued, adding 92,000 common shares as potential shares underlying the rights. In addition, 24,800 common shares were issued through the exercise of stock acquisition rights during the quarter. - FY2024-Q3MaterialisedAnnual report
「1 September 2023–30 November 2023 (Note 1) Common shares 6,600 (Note 1) Resulting from the exercise of stock acquisition rights. 2. Between 1 December 2023 and 31 December 2023, the exercise of stock acquisition rights increased the total number of issued shares by 2,900 common shares and capital stock by ¥725 thousand.」
During the third quarter, 6,600 common shares were issued through the exercise of stock acquisition rights, and the issuance of a further 2,900 shares in December before the filing date is also disclosed. - FY2024-Q2MaterialisedAnnual report
「1 June 2023–31 August 2023 (Note 1) Common shares 10,700 (Note 1) Resulting from the exercise of stock acquisition rights. 2. Between 1 September 2023 and 30 September 2023, the exercise of stock acquisition rights increased the total number of issued shares by 4,700 and capital stock by ¥1.300 million.」
During the second quarter, 10,700 common shares were issued through the exercise of stock acquisition rights, and the issuance of a further 4,700 shares in September 2023 is also disclosed, indicating that share issuance capable of causing dilution has continued. - FY2024-Q1MaterialisedAnnual report
「1 March 2023–31 May 2023 (Note 2) Common shares 33,400 …… (Note 2) Resulting from the exercise of stock acquisition rights.」
During the first quarter, 33,400 common shares were issued through the exercise of stock acquisition rights, confirming that share issuance capable of causing dilution continued to occur in practice. - FY2023-Q3MaterialisedAnnual report
「1 September 2022–30 November 2022 (Notes 1 and 2) Common shares 2,350」
During the third quarter, 2,350 common shares were issued through the exercise of stock acquisition rights, and the issuance of a further 2,750 shares in December 2022 is also disclosed, confirming that share issuance continued to occur in practice. - FY2023-Q2MaterialisedAnnual report
「1 June 2022–31 August 2022 (Notes 1 and 2) Common shares 21,800 5,555 439,593 － 347,630 (Note 1) Resulting from the exercise of stock acquisition rights.」
During the second quarter, 21,800 common shares were issued through the exercise of stock acquisition rights, increasing capital stock by ¥5.555 million. The issuance of a further 1,050 shares by the filing date is also disclosed. - FY2023-Q1MaterialisedAnnual report
「This was due to the exercise of stock acquisition rights.」
Between March and May 2022, 68,050 common shares were issued through the exercise of stock acquisition rights, increasing capital stock by ¥12.014 million. Shares continued to be issued through the exercise of stock acquisition rights. - FY2022-Q3WorsenedAnnual report
「As of the end of the current quarterly consolidated accounting period, potential shares, including class shares and stock acquisition rights issued for the acquisition of Coleman Research Group, Inc. and stock acquisition rights issued to the Company's officers and employees, totaled 3,184,738, equivalent to 34.9% of the 9,116,042 issued shares, including class shares and excluding treasury shares.」
The issuance of class shares and stock acquisition rights to finance the acquisition increased potential shares to 3,184,738, equivalent to 34.9% of the total number of issued shares. - FY2022-Q1MaterialisedAnnual report
「1 March 2021–31 May 2021 (Note 1) 39,700 8,829,150 5,830 393,996 － 347,630 (Note 1) Resulting from the exercise of stock acquisition rights.」
During the quarter, 39,700 common shares were issued through the exercise of stock acquisition rights, increasing capital stock by ¥5.830 million. The exercise of potential shares continued to occur in practice. - FY2021MaterialisedAnnual report
「As of the filing date of this document, the number of potential shares represented by stock acquisition rights was 553,650, equivalent to 6.3% of the 8,789,450 issued shares.」
Shares were also issued through the exercise of stock acquisition rights during the current period. As of the filing date, potential shares totaled 553,650, equivalent to 6.3% of the total number of issued shares. - FY2021-Q3MaterialisedAnnual report
「Change in total number of issued shares (shares) 126,700 Change in capital stock (¥ thousands) 15,014 1. Resulting from the exercise of stock acquisition rights.」
Between September and November 2020, 126,700 shares were issued through the exercise of stock acquisition rights, increasing capital stock by ¥15.014 million. - FY2021-Q2MaterialisedAnnual report
「Between 1 September 2020 and 30 September 2020, the exercise of stock acquisition rights increased the total number of issued shares by 33,600 and capital stock by ¥2.458 million.」
The disclosure states that shares were actually issued through the exercise of stock acquisition rights. It does not describe any impact on the share price. - FY2020First statedAnnual report
「As of the filing date of this document, the number of potential shares represented by stock acquisition rights was 1,157,600, equivalent to 14.1% of the 8,185,000 issued shares.」
The Company grants stock acquisition rights as an incentive for officers and employees to increase corporate value over the long term, while disclosing the potential for dilution upon exercise.